|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Biomarkers were the strongest predictors of cause-specific death: a doubling of troponin T was most strongly associated with sudden death (hazard ratio [HR], 1.48; P<0.001), NT-proBNP with heart failure death (HR, 1.62; P<0.001), and growth differentiation factor-15 with bleeding death (HR, 1.72; P=0.028).
|
29871978 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
NT-proBNP and MR-proANP were lower in obese vs. non-obese HF individuals (p = 0.013 and p = 0.01, respectively), whereas GDF-15 was similar and MR-proADM was higher in obese vs. non-obese HF individuals.
|
28004184 |
2017 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study we compared the plasma levels of NT-proBNP versus GDF-15 in patients with HF in AF versus sinus rhythm (SR).
|
31263996 |
2020 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
GDF-15 is a promising biomarker for prediction of HF and death due to CHD in the general population, which may provide prognostic information to already established clinical biomarkers.
|
29771963 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Pooled results showed that overexpression of GDF-15 was associated with poor survival in heart failure patients (log unit GDF-15: hazard ratio = 1.86, 95% CI = 1.37-2.52).
|
27454651 |
2017 |
|
Heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Each 20% increment in baseline GDF-15 value was associated with a higher risk of mortality [adjusted hazard ratio (HR) 1.13, 95% confidence interval (CI) 1.08-1.18, P < 0.001], the combined endpoint of CV death or hospitalization for heart failure (adjusted HR 1.09, 95% CI 1.05-1.14, P < 0.001) and heart failure death (adjusted HR 1.16, 95% CI 1.05-1.28, P < 0.001).
|
30204280 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
As well, GDF-15 was found a prognostic biomarker of heart failure and acute coronary syndrome.
|
21718220 |
2011 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
GDF-15 reflects chronic disease burden and acute perturbations in HF and responds to improvements in hemodynamic status.
|
28062617 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, we evaluated whether GDF-15 was associated with CV death or heart failure (HF) across the spectrum of risk in non-ST-segment elevation (NSTE)-ACS.
|
30710475 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to evaluate the prognostic impact of plasma GDF-15 and BNP in acute HF.
|
30144302 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
CTD_human |
Little is known about GDF-15 as a biomarker in patients with heart failure.
|
20855664 |
2010 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
GDF-15 and left ventricular mass index (LVMI) were significantly increased as early as the pre-clinical HF stage.
|
30019695 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Next-generation biomarkers including soluble source of tumorigenicity 2 (sST2), growth differentiation factor-15 (GDF-15), galectin-3 (Gal-3) and diverse microribonucleic acids (miRNAs) may have additional benefit in assessment of cardiac remodeling or differentiation of HF subtypes.
|
29682806 |
2018 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, clinical studies indicate that circulating, mature GDF15 is an independent biomarker for heart failure.
|
30104250 |
2018 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In patients with acute coronary syndrome, baseline levels of NT-proBNP and GDF-15 were strong markers associated with all-cause death based on their associations with death due to heart failure as well as due to arrhythmia and sudden cardiac death.
|
30427997 |
2018 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We assessed GDF-15 levels in 910 patients enrolled in the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) trial, a randomized clinical trial of exercise training in patients with HFrEF.Median follow-up was 30 months.
|
28958347 |
2017 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Role of GDF-15 in Heart Failure Patients With Chronic Kidney Disease.
|
30935637 |
2019 |
|
Heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We aimed to analyse the association between high-level growth-differentiation factor-15 (GDF-15) and mortality, recurrent MI and heart failure compared to low-level GDF-15 in patients with acute coronary syndrome (ACS).
|
31029521 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Higher NT-proBNP, hsTnT, and GDF-15 were also associated with a greater risk of HF with reduced EF; while higher NT-proBNP GDF-15 and sST2 were associated with HF with preserved EF.
|
31645163 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
GDF-15, a member of the transforming growth factor beta superfamily, regulates inflammatory and apoptotic pathways in various diseases, such as heart failure, kidney dysfunction, and cancer.
|
31476622 |
2019 |
|
Heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Elevated GDF-15 concentration was also associated with an increased rate of heart failure.
|
29866459 |
2018 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
GDF-15 and left ventricular mass index (LVMI) were significantly increased as early as the pre-clinical HF stage.
|
30019695 |
2018 |
|
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study we compared the plasma levels of NT-proBNP versus GDF-15 in patients with HF in AF versus sinus rhythm (SR).
|
31263996 |
2020 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Because myocardial NRG-1/ErbB signaling has been documented to be impaired during HF associated with type 1 DM, we examined whether enhancement of NRG-1β signaling via exogenous administration of recombinant NRG-1β could exert beneficial effects against post-MI HF in the type 1 diabetic heart.
|
28870731 |
2017 |
|
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
GDF-15 is induced in hypertrophic and dilated cardiomyopathy after volume overload, ischemia, and heart failure.
|
31663791 |
2020 |